Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [hepatology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

2 papers

TDX-2026-00021

Transjugular Intrahepatic Portosystemic Shunt (TIPS) versus Serial Large-Volume Paracentesis for Refractory Ascites in Cirrhosis with MELD 18: A Clinical Decision Analysis and Evidence Synthesis

Patients with advanced cirrhosis frequently develop refractory ascites, a significant cause of morbidity and mortality. Management options include serial large-volume paracentesis (LVP) and transjugular intrahepatic portosystemic shunt (TIPS). This paper synthesizes expert clinical perspectives and current literature to address the optimal management strategy for a 56-year-old male with alcohol-related cirrhosis, Child-Pugh C, and a MELD score of 18, experiencing refractory ascites requiring frequent LVP. The discussion focuses on the efficacy, safety, and transplant implications of TIPS compared to LVP. Evidence from meta-analyses and real-world cohorts suggests TIPS offers superior ascites control and potential transplant-free survival benefits, particularly in carefully selected patients. While a MELD score of 18 approaches a critical threshold for increased post-TIPS mortality, factors such as sustained abstinence, absence of current hepatic encephalopathy, and technical feasibility favor TIPS in this specific case. The interaction of TIPS with liver transplant candidacy and surgical complexity is also explored, indicating minimal adverse impact. This analysis underscores the importance of individualized risk-benefit assessment in managing refractory ascites at the MELD 18 threshold, advocating for TIPS with a tailored protocol to mitigate risks and improve patient outcomes while awaiting liver transplantation.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 62 votes 9 Apr 2026

TDX-2026-00004

Anticoagulation Strategies for Portal Vein Thrombosis in Cirrhotic Patients: A Community Peer-Reviewed Clinical Consensus

Background: Portal vein thrombosis (PVT) is a common complication of cirrhosis, significantly impacting patient outcomes and transplant candidacy. The management of PVT in cirrhotic patients is complex due to a rebalanced hemostatic system, making traditional coagulation parameters unreliable and raising concerns about both bleeding and thrombotic risks. This paper synthesizes expert opinions on anticoagulation strategies for incidental PVT in Child-Pugh B cirrhosis. Methods: This study leveraged a community peer-review platform, tachyDx, where a clinical scenario involving a 52-year-old male with Child-Pugh B cirrhosis and incidental main PVT was presented. Three verified specialist physicians contributed detailed responses, which were further peer-voted by 68 community members. The discussion focused on INR interpretation, choice of anticoagulant, duration of therapy, and indications for transjugular intrahepatic portosystemic shunt (TIPS). Results: Expert consensus highlighted that INR is an unreliable marker of hemostasis in cirrhosis, advocating for clinical assessment and potentially viscoelastic testing. Low molecular weight heparin (LMWH) was preferred over direct oral anticoagulants (DOACs) in Child-Pugh B cirrhosis due to limited safety data and hepatic metabolism concerns, with specific platelet count-based dosing recommendations. Anticoagulation for at least 6 months, or until liver transplant, was recommended for main PVT. TIPS was reserved for failed anticoagulation or complications of portal hypertension. The importance of ruling out pylephlebitis was also emphasized. Conclusions: The management of PVT in cirrhotic patients necessitates a nuanced, multidisciplinary approach. LMWH appears to be the preferred initial anticoagulant in Child-Pugh B cirrhosis, guided by clinical factors and platelet counts. Further research, particularly randomized controlled trials, is warranted to establish the long-term safety and efficacy of DOACs in this vulnerable population.

3 contributors 68 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3infectious-disease3surgery3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1